Betta Pharmaceuticals Co., Ltd.: Lung Neoplasms trials

The registry lists 23 Lung Neoplasms studies with Betta Pharmaceuticals Co., Ltd. as lead sponsor. 4 are open to participants now and 1 have results posted.

Phase 1 4Phase 2 13Phase 3 4Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Phase 2
• Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsRecruitingNCT06041776Phase 3
• Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruitingNCT06015568Phase 1
• Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
• Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Phase 3Results posted
• Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingNCT05007938Phase 2
• CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
• Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2
• Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerStatus unknownNCT03396185Phase 2
• Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerStatus unknownNCT03349203Phase 2
• Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung CancerStatus unknownNCT03346811Phase 2
• X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibActive, not recruitingNCT03215693Phase 2
• Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
• Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsCompletedNCT02914990Phase 1
• Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
• Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Phase 2
• Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLCStatus unknownNCT02194556Phase 4
• Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownNCT02066870Phase 1
• Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic InsufficiencyStatus unknownNCT02062515Phase 2
• High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseStatus unknownNCT02027090Phase 2
• Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR MutationStatus unknownNCT01929200Phase 2
• Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib TherapySuspendedNCT01720901Phase 4